CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information: Achillion's hepatitis C drug cures all patients in mid-stage trial

Achillion's hepatitis C drug cures all patients in mid-stage trial

Last Updated: 2014-08-15

By Reutes Staff

(Reuters) - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

The mid-stage trial tested Achillion's second-generation NS5A inhibitor ACH-3102 in 12 patients in combination with sofosbuvir (Sovaldi) from Gilead Sciences.

Achillion said it would begin treating 12 additional patients for six weeks with a once-daily dose of ACH-3102 and sofosbuvir.

The trial excluded the older hepatitis C drug ribavirin, which can cause rashes, anemia and other side effects.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.